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p63, a member of the p53 superfamily, is an essential cell fate determinant for stratiﬁed epithelium. Deﬁciency of
p63 leads to lack of differentiated epithelium from the skin and the presence of trace undifferentiated cells left in the
dermis. We found that transcriptionally active isoforms of p63, TAp63b and TAp63c, activated the skin-specific
promoter of bullous pemphigoid antigen 1 (BPAG-1). The p63-response element was localized between bases 177
and 153 upstream of exon 1 in the BPAG-1e promoter, whereas regions surrounding the response element
suppressed transcriptional responses to p53 and TAp73b, resulting in p63-specific activation of the promoter. This
represents a novel molecular mechanism by which target gene induction by p63 is distinguished from induction by
other p53 family members.
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p63 is a member of the p53 tumor suppressor gene family.
Similar to p53, p63 is a transcription factor that activates
target genes through sequence-specific DNA binding (Sch-
male and Bamberger, 1997; Osada et al, 1998; Senoo et al,
1998; Trink et al, 1998; Yang et al, 1998). The p63 gene
plays a pivotal role in skin development and the p63-defi-
cient mouse displays defects in its skin epithelium and ap-
pendages. The surface epithelium of p63 knockout mice
consists of a single cell layer that fails to differentiate into
mature stratified epithelium. This altered morphology is due
to crucial roles for p63 in the maintenance of stem cells in
the skin cell lineage or through failure of commitment to the
stratified epithelial lineage (Mills et al, 1999; Yang et al,
1999). It has been reported that mutations in p63 cause
several ectodermal dysplasia and limb abnormalities, such
as EEC (ectodactyly, ectodermal dysplasia), AEC (an-
kyloblepharon, ectodermal dysplasia, clefting), LMS (limb-
mammary syndrome), SHFM (split hand/foot malformation),
and ADULT (acro-dermato-ungual-lacrimal-tooth) syn-
dromes. The ectodermal symptoms of these syndromes
are dependent on the specific types of p63 mutations (Celli
et al, 1999; Ianakiev et al, 2000; Amiel et al, 2001; McGrath
et al, 2001; van Bokhoven and Brunner, 2002).
Recently, in an effort to identify candidate p63 target
genes by microarray analysis, we identified several plakin
family genes, including bullous pemphigoid antigen 1
(BPAG-1), envoplakin, and periplakin, induced by TAp63b
and/or TAp63g.1 Plakins are cytolinker proteins that asso-
ciate with cytoskeletal elements and junctional complexes
(Leung et al, 2001; Leung et al, 2002). Mutations of plakin
genes or autoimmune diseases targeting plakins cause
skin blistering disorders (Borradori and Sonnenberg, 1999;
Leung et al, 2002). In the EVPL promoter, a p63-specific
response element was found in the 50 promoter region.
Moreover, we found that BPAG-1 was uniquely activated by
p63, not by p53 or p73.
The human BPAG-1 gene has various alternatively
spliced isoforms (Okumura et al, 2002; Roper et al, 2002).
These isoforms are expressed from 4 different promoters,
P1, P2, P3, and Pe, and exhibit tissue-specific expression
(Roper et al, 2002). One of the major transcripts, BPAG1-e,
is induced from promoter Pe and is expressed mainly in the
epidermis. Several skin-specific regulatory elements on the
BPAG1-e promoter have been described (Tamai et al, 1993,
1994a, b, 1995; Matsuzaki et al, 2003). The effect of p63 on
the regulation of BPAG-1e promoter activity, however, has
not been reported.
To clarify the p63-specific transactivation mechanism of
the BPAG-1e promoter, we examined the  1.1 kb region
upstream of exon 1 and identified a p53-type response el-
ement at 177 to 153. The response element consisted of
two half-sites of a p53-type binding motif (RRRCWWGYYY)
(el-Deiry et al, 1992; Vogelstein and Kinzler, 1992) with sev-
eral mismatches and a 5-bp gap between the two half-sites.
Although the response element itself was activated by all
p53 family members, the surrounding sequences sup-
pressed activation by p53 and p73. Our studies thus dem-
onstrate a novel mechanism of expression regulation, which
confers p63-specific gene activation.
Results
p63-deﬁcient mice lack skin BPAG-1 expression Re-
cently we demonstrated that BPAG-1 was specifically in-
Abbreviations: BPAG, bullous pemphigoid antigen 1; EEC, ecto-
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duced by TAp63g in a Saos2-inducible cell line by oligonuc-
leotide microarray analysis.2 As shown in Fig 1, BPAG-1
was endogenously expressed at low levels and was clearly
upregulated by TAp63b induction. To test whether BPAG-1
expression was also affected by p63 in vivo, we stained
p63-deficient mouse skin with BPAG-1 antibody (Fig 2).
Consistent with previous reports, p63/ mouse skin did
not have stratified epithelium, displaying only remnants of
undifferentiated cells on the surface of the dermis. BPAG-1
was detected throughout the entire epithelium in wild-type
mouse skin, especially in the basal layer of the epithelium
and also relatively weakly in the dermis, which is similar to
the staining pattern of TAp63b and TAp63g (Nylander et al,
2002). BPAG-1 was, however, not detected in the single
layer epithelium on the surface of the p63/ mouse. The
4A4-p63 antibody stained the basal layer of the stratified
epithelium in wild-type p63 mice (Yang et al, 1998). Although
the 4A4 antibody can recognize all p63 isoforms, the tran-
scriptionally active isoforms, TAp63b and TAp63g, which are
expressed suprabasally in stratified epithelium, are very la-
bile and may not be detected by the 4A4 antibody (Osada
et al, 2001; Ghioni et al, 2002; Nylander et al, 2002; Serber
et al, 2002). DNp63a has also been shown to act as a
transactivator in keratinocytes and is the most predominant
isoform in skin (Dohn et al, 2001 and King et al, 2003). These
results show the coordinate expression between p63 and
BPAG-1 in the skin. p53 and p73 protein expression were
also examined in p63/ mouse skin; however, no protein
expression was detected in the single layer epithelium.
The BPAG-1 promoter is activated by some p63 family
members To examine the ability of p63 to activate skin-
specific BPAG-1 expression, we cloned the 1.1 kb BPAG-
1e promoter, which induces BPAG-1 expression specifically
in the skin, and examined its response to p63 and also to
other p53 family members. Figure 3a shows the transacti-
vation activity of various p53 family members on the BPAG-
1e promoter in Saos2 cells. Our rationale for using Saos2
cells is that the Saos2 cell line has a homozygous deletion
of p53 and thus has been extensively used in p53 research
(Chen et al, 1990; Diller et al, 1990). Whereas various levels
of p63 expression in Saos2 cells have been reported by
other investigators, the Saos2 cells used in our laboratory
express undetectable levels of p53, p63, and p73 proteins
(Wu et al, 2005) (Fig 3c). Thus, transactivation is presumably
not inhibited by either mutant p53 or DN isoforms of p63
and/or p73. To study BPAG-1 promoter regulation in a rel-
evant cellular environment, we also used HaCaT keratin-
ocytes, which express DNp63a and mutant p53 (Lehman
et al, 1993; Papoutsaki et al, 2004). DNp63a has also been
shown to exhibit transactivation ability in keratinocytes
(Dohn et al, 2001; King et al, 2003).
In both cell lines, TAp63b and TAp63g strongly activated
the reporter, and DNp63b, which has a second activation
domain in its carboxy-terminus (Ghioni et al, 2002; Serber
et al, 2002), activated the reporter with less efficiency than
TAp63b (Fig 3a and b). Other p63 isoforms and p53 family
members activated the promoter less than 10-fold when
compared to mock transfection. Transactivation levels were
relatively lower in HaCaT cells than in Saos2 cells except for
transactivation by TAp63b, perhaps due to a dominant neg-
ative effect of mutant p53 and/or DNp63a. To test for po-
tential synergistic activation or dominant negative inhibition
of promoter activity, p53 or TAp73b were co-transfected
with TAp63g or TAp63b. No activation or repression, how-
ever, was observed in these co-transfection experiments
(data not shown). Figure 3c shows the protein expression of
exogenously expressed p53, p63, and p73 in Saos2 and
HaCaT cells. Consistent with previous reports, TAp63b and
TAp63g isoforms exhibited lower steady state levels of pro-
tein expression than TAp63a and DNp63 isoforms (Osada
et al, 2001; Ghioni et al, 2002; Serber et al, 2002). Thus, the
higher levels of BPAG-1e promoter activation by TAp63b
and TAp63g were not due to higher levels of protein
expression.
TAp63b and TAp63c respond to the p53-type response
element in the 177 to 153 region of the BPAG-1e
promoter In order to clarify the p63-response element in
the BPAG-1e promoter, we made a series of 50  100 bp
deletion plasmids. The deletion plasmids were co-trans-
fected with TAp63b, and luciferase activity was measured
in Saos2 cells (Fig 4a). From 1072 to 192, luciferase
activity gradually decreased. Between 192 and 152, the
transactivation by TAp63b was completely lost. The same
sets of transfections were performed in HaCaT cells in order
to examine the effect of other tissue-specific transcription
factors on BPAG-1e promoter activation by p63. Similar to
the results seen in Saos2 cells, the region between 192
and 152 was critical for transactivation by TAp63b. In the
case of HaCaT cells, the BPAG-1e promoter was also ac-
tivated by endogenous transcription factors. Between 272
and 192, there was a strong cis-element responsive to
tissue-specific transcription factors and the region corre-
sponds to KRE3 which was previously reported (Tamai et al,
1995). This tissue-specific responsive region (272 to
192) was, however, distinguished from the p63 respon-
sive region (192 to 152).
In the p63 responsive region’s proximity, four potential
p53-type response element half-sites, each with two to
three mismatches, were observed, each within 13 bp of the
next half-site (190 to 136, Fig 5). In order to determine
which element responds to p63, six different combinations
of putative elements were cloned into the luciferase plasmid
and examined for activation by p53 family members in Sa-
os2 and HaCaT cells. As shown in Fig 5, the combination of
elements 2 and 3 was activated by p53, TAp63g, TAp73b,
Figure 1
Bullous pemphigoid antigen 1 (BPAG)-1 mRNA induction in TAp63-
b-inducible Saos2 cells. Cells were treated with tetracycline to induce
p53, TAp63b, and TAp73b and harvested for BPAG-1 expression anal-
ysis by RT-PCR. BPAG-1 was clearly induced by TAp63b.
2Manuscript, submitted.
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and especially TAp63b. Reporters that contained elements
1 or 4 were less activated by p53 and TAp73b than reporters
containing elements 2 and 3. These data suggest that el-
ements 2 and 3 constitute the two half-sites of the p63-
response element and that the specific activation of the
BPAG-1e promoter by p63 was due to the presence of
suppressive sequences for p53 and TAp73b surrounding
the response element.
To test whether p63 proteins bind to the endogenous
BPAG-1e promoter, we performed a chromatin immuno-
precipitation assay with ectopic expression of p53 family
members in Saos2 cells. As shown in Fig 6, the BPAG-1e
promoter was PCR-amplified from the TAp63b and TAp63g
precipitates but not from p53 or TAp73b precipitates. These
data demonstrate the unique binding affinity of p63 to the
BPAG-1e promoter in vivo.
Figure 2
Immunohistochemical staining of bullous pe-
mphigoid antigen 1 (BPAG)-1 in p63þ /þ and
p63/ mice skin. (a–c) e p63þ /þ and (d–h)
p63/. a and d were stained with hematoxylin–
eosin, b and e were stained for p63, c and f were
stained for BPAG-1, g was stained for p53 and h
was stained for p73. Absence of p63 and BPAG-
1 staining are evident in the skin of p63 knockout
mice.
Figure 3
Activation of the bullous pemphigoid antigen 1 (BPAG-1)e promoter by p63. (a) A luciferase plasmid containing 1.1 kb of the BPAG-1e promoter
upstream of the luciferase gene was co-transfected into Saos2 cells with p53 family gene expression plasmids. Y-axis represents fold activation of
luciferase activity exhibited by the BPAG-1e (1072/þ 27) promoter in the presence of p53 family members. Luciferase activity of the BPAG-1e
promoter with empty pcDNA3.1 was arbitrarily set to 1. (b) The same set of reporter assays was performed in HaCaT keratinocyte cells. (c)
Immunoblotting of exogenously expressed p53, p63, and p73 protein in HaCaT and Saos2 cells.
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SHFM and EEC syndrome-derived mutants differentially
activate the BPAG-1e promoter SHFM and EEC syn-
dromes are hereditary syndromes characterized by muta-
tions in the DNA binding domain of p63 (Brunner et al, 2002;
van Bokhoven and McKeon, 2002). Individuals with EEC
syndrome exhibit various skin and appendage symptoms,
whereas individuals with SHFM do not exhibit such symp-
toms. The p63 mutations present in EEC syndrome, such as
R204, R279, R280, and R304, correspond to R173, R248,
R249, and R275 in p53. These p53 mutations have typically
been found in human cancers and are located in the res-
idues that have direct contact with DNA. On the other hand,
the SHFM mutations, K193 and K194, presumably do not
involve residues that have direct contact with DNA and are
not assumed to have a severe inhibitory effect on DNA
binding. In order to clarify the functional differences be-
tween EEC syndrome-derived and SHFM-derived p63 mu-
tations, we examined the effect of these mutations on the
transcriptional activity of three p63 target gene promoters:
BPAG-1e as a p63-specific target, WNT-4 as a target for
p63 and p73, and CLCA-2 as a common target for all p53
family members.
Figure 7a shows the transactivation activity of SHFM and
EEC syndrome-derived mutant p63 proteins on the BPAG-
1e promoter. K193E and K194E, which were derived from
SHFM, retained 30% to 100% transactivation activity com-
pared to wild-type p63. On the other hand, the mutants
derived from EEC syndrome almost completely lost all
transactivation function on the BPAG-1e promoter. On the
WNT-4 promoter, the K193E and K194E mutations of
TAp63g exhibited 20% to 25% transactivation ability com-
pared with wild-type TAp63g (Fig 7b). On the other hand,
TAp63b and TAp63g with K193E or K194E mutations acti-
vated the CLCA-2 promoter to virtually to same extent as
wild-type proteins (Fig 7c). The mutations of EEC syn-
drome-derived mutants resulted in loss of transactivation
activity on all three promoters (Fig 5a–c). Based on these
observations, we speculate that the mutations of EEC syn-
dromes are loss of function mutations, whereas the mutants
derived from SHFM mutations possess differential transac-
tivation activity depending on the promoter structure. These
differences could underlie the differential skin symptoms
observed between these two syndromes.
Discussion
p63 plays an essential role in stratified epithelium develop-
ment. The p63-deficient mouse lacks stratified epithelium
due to the absence of stem cells in the skin and/or the
inhibition of commitment to the stratified epithelium lineage
(Mills et al, 1999; Yang et al, 1999). DNp63a is highly ex-
pressed in holoclone-generating keratinocytes, which are
thought to constitute a peripheral stem cell fraction in the
skin (Pellegrini et al, 2001). TAp63a expression under the
control of the Keratin 5 promoter induces the early stages of
differentiation in skin but inhibits terminal differentiation
(Koster et al, 2004). By using a TA-specific antibody, it has
been shown that TAp63 proteins are expressed in the sup-
ra-basal layer of stratified epithelium (Nylander et al, 2002).
DNp63a, a major isoform expressed in skin, produces
dominant negative effects against TAp63 isoforms (Yang
et al, 1998); however, DNp63a also functions as a se-
quence-specific transcription factor in keratinocytes (Dohn
et al, 2001; King et al, 2003). Thus, clarifying the target
genes of p63 via sequence-specific transcriptional activa-
tion is important for understanding skin development.
We analyzed the BPAG-1e promoter in two cell lines,
Saos2 and HaCaT. In both cell systems, we found that p63
activated the BPAG-1e promoter to a higher extent than
other p53 family members. Interestingly, the surrounding
sequences suppressed transcriptional activation by p53
and TAp73b. Previously, we found two criteria for p63-
specific transactivation: (1) the response element (RRRCW
WGYYY, RE1) itself has higher affinity for p63 than for p53
and (2) the p63-response element (RE2) together with the
RRRCWWGYYY (RE1)-type response element results in
p63-specific transactivation (see footnote 2). In this study,
we demonstrated that the structure exhibited by the BPAG-
Figure 4
p63-response elements are located between 192 and 152 in the
bullous pemphigoid antigen 1 (BPAG-1)e promoter. (a) Serial dele-
tion mutants of BPAG-1e promoter plasmids were co-transfected with
TAp63b and luciferase activity was measured in Saos2 (a) and HaCaT
(b) cells. Luciferase activity exhibited by cells transfected with pGL-
3Basic was arbitrarily set to 1. The transcriptionally active isoforms of
p53 family members have a general repressor effect on transcription;
thus, the values were normalized by using an internal control vector for
Renilla luciferase (Johnson et al, 2003). p63-specific activation is rep-
resented by TAp63b/pcDNA3.1 ratio values. () indicates location of
p63-response elements.
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1e promoter uncovers another pathway for specific p63
activation. Several p63 or p73 unique target genes, such as
JAG1, JAG2, and IL4R, have been reported (Sasaki et al,
2002, 2003). In the case of JAG1 and IL4R, the p63- and
p73-response elements were reported to reside within their
introns. We also examined the 5 tandem repeats of p53-
type binding elements in intron 2 of the JAG2 gene (un-
published data). However, these response elements them-
selves are activated not only by p63 or p73, but also by
p53. Thus, it is likely that suppressive elements specific for
p53, and not for p63 or p73, are located elsewhere
in these gene promoters as in the case of the BPAG-1e
promoter.
The mechanisms responsible for suppression of trans-
activation by p53 and p73 based on the sequences sur-
rounding the p63-RE in the BPAG-1e promoter are
unknown. In vitro protein–DNA interaction analysis by elect-
romobility shift analysis using 177/153 and 190/136
oligonucleotides did not show p63-specific binding. These
oligonucleotides gave very little to no binding signals for
p53 and p63, presumably due to the 5-base gap between
each half-site, a result which is consistent with our previous
EMSA observations (see footnote 2). The sequences flank-
ing the p63-RE have two potential half-sites within a 13-bp
gap. However, both sequences functioned as suppressive
elements rather than activating elements. The obvious dif-
ferences between these half-sites and the canonical p53-
type response element (RRRCWWGYYY) are: (1) the 50 el-
ement, 191/181, has a mismatch in the fourth position
(C to G) and (2) the 30 element, 145/136, has a 7-bp gap
between it and the next response element, which is rela-
tively rare in previously reported p53-RE (Tokino et al, 1994;
Figure 5
Identification of the p63-response element in the bullous pemphigoid antigen 1 (BPAG-1)e promoter. The putative p63-response elements
were cloned into the pGL3-Basic plasmid and luciferase activity was examined upon co-transfection with p53, TAp63b, TAp63g and TAp73b in
Saos2 (a) and HaCaT (b) cells. 191/181 (element 1), 177/168 (element 2), 162/153 (element 3), and 145/136 (element 4) are putative
p63-response elements. Underlined bases are mismatched bases from the p53 consensus sequence.
Figure 6
Chromatin immunoprecipitation of the bullous pemphigoid antigen
1 (BPAG-1)e promoter by p63 protein. Chromatin immunoprecipita-
tion analysis using ectopically expressed FLAG-tagged p53 family pro-
teins. After induction of p53, TAp63b, TAp63g, and TAp73b with 1 mg
per mL of tetracycline, cells were fixed with formaldehyde and immuno-
precipitated with anti-FLAG antibody. Only p63 precipitated the BPAG-
1e promoter fragment. CLCA-2 (calcium-dependent chloride channel-
2) was used as a positive control for all p53 family members. The
CLCA-2 promoter has a p53-type response element in the 73 to 54
region of its promoter and is activated by p53, p63, and p73.
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Inga et al, 2002). These differences may contribute to the
suppressive effect of the flanking elements.
It has been shown that several hereditary epidermal and/
or limb anomalies are caused by p63 mutations (Celli et al,
1999; Ianakiev et al, 2000; Amiel et al, 2001; McGrath et al,
2001; van Bokhoven and Brunner, 2002). Although both
SHFM and EEC syndromes have mutations in the DNA
binding domain of the p63 protein, EEC syndrome mani-
fests epidermal abnormalities, whereas SHFM does not
(Brunner et al, 2002; van Bokhoven and McKeon, 2002). The
transactivation activity of the EEC syndrome-derived mu-
tants was almost completely lost, whereas that of the
mutants derived from SHFM varied depending on the
promoter. The SHFM-derived p63 mutants, K193E and
K194E, activated the CLCA-2 promoter to the same extent
or higher than their wild-type counterpart; on the other
hand, they were less active on the BPAG-1e and WNT-4
promoters when compared to wild-type. It is possible that
the lysine residues are modified by acetylation or binding to
ubiquitin-protein family members and thus modulate the
function of the wild-type p63 protein. The p63-response el-
ement in the CLCA-2 promoter has three mismatches in two
half-sites and no gap, whereas the response elements in the
BPAG-1e and WNT-4 promoters have six and five mis-
matches in two half-sites and a 5- and 1-bp gap between
the half-sites, respectively. We have previously shown that
an increased number of mismatches and presence of a gap
in the response element greatly reduce transactivation abil-
ity and protein-DNA binding (see footnote 2). The p63 lysine
mutants derived from SHFM might not be correctly modified
and it is possible that lack of proper modification more se-
verely affects DNA binding of less conserved consensus
sequences.
Recently, through microarray analysis, we obtained a list
of more than 100 candidate target genes, which were in-
duced by p63 and demonstrated a consensus sequence for
p63-specific transcriptional activation (see footnote 2). In-
cluded on this list were several plakin family genes, such as
EVPL, periplakin, and BPAG-1. These plakin family mem-
bers are components of hemidesmosomes in the epidermis.
Hemidesmosomes are junctional complexes that contri-
bute to the attachment of epithelial cells to the underlying
basement membrane predominantly in stratified epithelium
(Borradori and Sonnenberg, 1999). Genetic mutations of
hemidesmosome components or autoimmunity to their
components cause diseases manifested by dermo-epider-
mal separation, including bullous pemphigoid and epider-
molysis bullosa (Borradori and Sonnenberg, 1999). Koster
et al (2004) showed that TAp63s induced Keratin 5 and
Keratin 14, which are intermediate filaments that bind to the
BPAG-1e protein at the hemidesmosome. We also demon-
strated that BPAG-2, a transmembrane component of the
hemidesmosome that serves as a transmembrane receptor
connecting the cell interior to the extracellular matrix, was
induced by TAp63g (Stappenbeck et al, 1993; Fontao et al,
2003). Thus, the deficiency of mature epidermis in the
p63/ mouse could be due, at least in part, to the dys-
regulation of hemidesmosome components in the skin.
Materials and Methods
RT-PCR The First Strand cDNA Synthesis Kit (Invitrogen, Carls-
bad, California) was used for reverse transcription. PCR was per-
formed with recombinant Taq polymerase (Invitrogen) as follows:
30 cycles consisting of 941C for 1 min, 581C for 1 min and 721C for
30 s. Primer sequences are BPAG7210F, TCAGGGCAGCAATAT-
CAGTG and BPAG7418R, ACTAACCGGCTCAGCAAAGA.
Luciferase assay For luciferase analysis, one mg of expression
vector and 200 ng of pGL3-Basic reporter plasmid (Promega,
Madison, Wisconsin) were co-transfected by calcium-phosphate
into Saos2 cells in 24-well plates. Data reflect fold-change in lucif-
erase activity in experimental cells over cells co-transfected with
empty pGL3-Basic and pcDNA3.1-Hygro vectors unless otherwise
Figure 7
Differential regulation of p63 target gene promoters by split hand/
foot malformation (SHFM) and ectodactyly, ectodermal dysplasia
(EEC) syndrome-derived mutants. The transactivation activity of
TAp63b and TAp63g mutants derived from SHFM and EEC syndromes
were examined on the promoters of p63 target genes. K193E and
K194E were derived from SHFM, and R204W, R279H, R280C, and
R304Q were derived from EEC syndrome mutants. (a) BPAG-1e pro-
moter (1072/þ27), (b) WNT-4 promoter (1200/37), and (c) CLCA-2
(calcium-dependent chloride channel-2) promoter (1241/þ101). Up-
per case bases represent p53-type response element half-sites and
underlined bases are mismatched bases from the p53 consensus
sequence.
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stated in the figure legend. Means and standard deviations were
calculated after three independent transfections.
Immunostaining p63þ / mice (Jackson Laboratory, Bar Harbor,
Maine) were mated and homozygous mutants were produced
(Mills et al, 1999). 18.5 dpc embryos were formalin fixed and em-
bedded in paraffin. Each representative section was stained by
hematoxylin and eosin (HE), and immunohistochemical detection
was performed with the avidin–biotin–peroxidase complex method
using Vectastain ABC Kits (Vector Laboratories, Burlingame, Cal-
ifornia). Antigen retrieval was achieved by five cycles of boiling and
cooling in 0.1 M citric acid and 0.1 M trisodium citrate. Monoclonal
anti-p63 4A4 antibody (Santa Cruz Biotechnology, Santa Cruz,
California) (1:100), polyclonal anti-BPAG1 C-17 (Santa Cruz Bio-
technology) (1:200) antibody, anti-p73 Ab-4 antibody (Neomarker,
Fremont, California) (1:100) and anti-p53 rabbit polyclonal antibody
(Neomarker) (1:100) were used. The antibodies were incubated at
41C overnight. The sections were developed with diaminobenzi-
dine and counterstained with hematoxylin. The ACU (animal care
and use) committee of Johns Hopkins University approved all de-
scribed studies.
Western blotting Total protein was extracted from cells with
sample lysis buffer (50 mM Tris-HCl (pH 6.8), 2% SDS, 6% (v/v) b-
mercaptoethanol and 10% glycerol) and run on a 9% SDS-polya-
crylamide gel. Proteins were transferred onto a nitrocellulose
membrane (Schleicher & Schuell, Limerick, Ireland) and blocked
with 3% skim milk/PBS-Tween20. Ab-8 (DO-7þBP53-12) anti-
body (Neomarker) was used to detect p53, 4A4 antibody (Santa
Cruz Biotechnology) was used to detect p63 and Ab-4 (ER-
13þER-15þGC-15) (Neomarker) was used to detect p73. Anti-
mouse IgG conjugated with horseradish peroxidase was used as
secondary antibody (Amersham-Pharmacia, Buckinghamshire,
England) and chemiluminescent signals were detected by Super-
signal WestPico Chemiluminescent Substrate Kit (Pierce, Rock-
ford, Illinois).
Inducible cell line Flp-in, T-Rex Saos2 cells have been described
elsewhere. p53, TAp63b, and TAp73b with and without a 2XHA tag
at the amino and 3XFLAG tag at the carboxyl terminus were sub-
cloned into the BamHI and XhoI sites of pcDNA5/FRT/TO (Invitro-
gen). The pcDNA5/FRT/TO expression constructs were introduced
along with the pOG44 (Invitrogen) plasmid into Flp-in, T-Rex Saos2
cells and the resulting cells were selected by resistance to
hygromycin. Final stable clones were induced with 1 mg per mL
tetracycline.
Plasmids The BPAG-1e promoter region (1072 to þ 27) was
PCR-amplified with BPAG1F-1072MluI, TGACACGCGTTGCCTAC
TACATTGGGTGGTTATG, and BPAG1Rþ 72XhoI, GATCCTCGAGC
TACTTCTAACGGTGAAAAGTGGC.
The amplified promoter fragment was cloned into the MluI and
XhoI sites of pGL3-Basic. Each truncation mutant was constructed
by using the following primers and cloning into the same site of
pGL3-Basic:
BPAG1F-983MluI, TGACACGCGTCCAGGTGCCACTGT-
TATTGTTT;
BPAG1F-892MluI, TGACACGCGTAAGCAATTGGTGTGG-
CACTCTC;
BPAG1F-778MluI, TGACACGCGTGGCTGGTTGGA-
TAAATGCCTTC;
BPAG1F-674MluI, TGACACGCGTTGGGAAAGAGC-
CAGTGTTCTTA;
BPAG1F-580MluI, TGACACGCGTCTACTTGGCACTTTATAG-
TAGG;
BPAG1F-459MluI, TGACACGCGTATGGAAGCG-
TACTTTGCTTCTC;
BPAG1F-355MluI, TGACACGCGTGCAGAAGTCAGACTAT-
GATTGG;
BPAG1F-272MluI, TGACACGCGTGACATCTGTGAGGCATCT-
GAGT;
BPAG1F-232MluI, TGACACGCGTAATTGGATGACTCTTAGTGC;
BPAG1F-192MluI, TGACACGCGTCTGCTTTGTTCATACTTG-
TAGG;
BPAG1F-152MluI, TGACACGCGTGGTTTTAATACAAGCTACAA;
and
BPAG1F-110MluI, TGACACGCGTCGAATGGCTTTAGGCTA-
GATTC.
The CLCA-2 promoter was PCR-amplified using the primers
CLCA2F-MluI, TGACACGCGTCCGTTTCCTAAATGCTACACTCCC,
and CLCA2R-XhoI, GATCCTCGAGGTTGTAGAGAAGCCTCCAGT
TCAC.
The fragment (1241/þ 101) was cloned into the MluI and XhoI
sites of pGL3-Basic. WNT-4 promoter plasmid was provided by Dr
Melissa H. Little at the University of Queensland, Australia (Sim
et al, 2002).
Response element oligonucleotides were cloned into the MluI
and XhoI sites of pGL3-Basic. The oligonuclelotide sequences
were as follows:
BPAG1-RE1234S, CGCGTCAGTGACGCCCAA
TCTGCCTGCTTTGTTCATACTTGTAGGGTTTT
AATACAAGCTACC;
BPAG1-RE1234A, TCGAGGTAGCTTGTATTAAAACCCTACAAG
TATGAACAAAGCAGGCAGATTGGGCGTCAC
TGA;
BPAG1-RE123S, CGCGTCAGTGACGCCCAATCTGCCTGCTTT
GTTCAT ACTTGTAGGC;
BPAG1-RE123A, TCGAGCCTACAAGTATGAACAAAGCAGGCA G
ATTGGGCGTCACTGA;
BPAG1-RE234S, CGCGTTCTGCCTGCTTTGTTCATACTTGTAG
GGTTTTAATACAAGCTACC;
BPAG1-RE234A, TCGAGGTAGCTTGTATTAAAACCCTACAAGTA
TGAACAAAGCAGGCAGAA;
BPAG1-RE12S, CGCGTCAGTGACGCCCAATCTGCCTGCTTTC;
BPAG1-RE12A, TCGAGAAAGCAGGCAGATTGGGCGTCACTGA;
BPAG1-RE23S, CGCGTTCTGCCTGCTTTGTTCATACTTGTAGGC;
BPAG1-RE23A, TCGAGCCTACAAGTATGAACAAAGCAGGCAGAA;
BPAG1-RE34S, CGCGTCATACTTGTAGGGTTTTAATACAAGCTAC
C; and
BPAG1-RE34A, TCGAGGTAGCTTGTATTAAAACCCTACAAGTATGA.
PCR-amplified 2XHA and 3XFLAG tagged p53, TAp63b, TAp63-
g, and TAp73b were cloned into the BamHI and XhoI sites of
pcDNA5/FRT/TO. The PCR primers are as follows:
hp53-2HAFBamHI, TGCATGGATCCCCACCATGTATCCGTAC-
GATGTACCTGACTATGCATATCCGTAC-
GATGTTCCAGACTATGCTATGGAG-
GAGCCGCAGTCAGATCCT;
hp53-3FLAGRXhoI, GAATCTCGAGTCACTTGTCATCGT-
CATCCTTGTAGTCGATGTCATGATCTTTA-
TAATCACCGTCATGGTCTTTGTAGTCGTCT-
GAGTCAGGCCCTTCTGT;
hp63TA-2HAFBamHI, TGCATGGATCCCCACCATGTATCCGTAC-
GATGTACCTGACTATGCATATCCGTAC-
GATGTTCCAGACTATGCTATGTCCCA-
GAGCACACAGACAAAT;
hp63b-3FLAGRXhoI, GAATCTCGAGTCACTTGTCATCGT-
CATCCTTGTAGTCGATGTCATGATCTTTA-
TAATCACCGTCATGGTCTTTGTAGTC-
GACTTGCCAGATCCTGACAAT;
hp63g-3FLAGRXhoI, GAATCTCGAGTCACTTGTCATCGT-
CATCCTTGTAGTCGATGTCATGATCTTTA-
TAATCACCGTCATGGTCTTTG-
TAGTCTGGGTACACTGATCGGTTTGG;
hp73TA-2HAFBamHI, TGCATGGATCCCCACCATGTATCCGTAC-
GATGTACCTGACTATGCATATCCGTAC-
GATGTTCCAGACTATGCTATGGCC-
CAGTCCACCGCCACCT; and
hp73b-3FLAGRXhoI, GAATCTCGAGTCACTTGTCATCGT-
CATCCTTGTAGTCGATGTCATGATCTTTA-
TAATCACCGTCATGGTCTTTG-
TAGTCGGGCCCCCAGGTCCTGACGAG.
Mutant TAp63b and TAp63g were made using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California).
The following primers were used for the mutagenesis:
K193Esense, ATGCCTGTCTACGAAAAAGCTGAGCACGTC;
K193Eanti, GACGTGCTCAGCTTTTTCGTAGACAGGCAT;
K194Esense, ATGCCTGTCTACAAAGAAGCTGAGCACGTC;
K194Eanti, GACGTGCTCAGCTTCTTTGTAGACAGGCAT;
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R204Wsense, ACGGAGGTGGTGAAGTGGTGCCCCAACCATGA
GC;
R204Wanti, GCTCATGGTTGGGGCACCACTTCACCACCTCCGT;
R279Hsense, GTTGGAGGGATGAACCACCGTCCAATTTTAATC
A;
R279Hanti, TGATTAAAATTGGACGGTGGTTCATCCCTCCAAC;
R280Csense, GGGATGAACCGCTGTCCAATTTTAATCATT;
R280Canti, AATGATTAAAATTGGACAGCGGTTCATCCC;
R304Qsense, CGCTGCTTTGAGGCCCAGATCTGTGCTTGCCC
AG; and
R304Qanti, CTGGGCAAGCACAGATCTGGGCCTCAAAGCAGC G.
Chromatin immunoprecipitation (ChIP) A Chromatin Immuno-
precipitation Kit (Upstate Cell Signaling Solutions, Waltham,
Massachusetts) was used for ChIP analysis according to the man-
ufacturer’s protocol. FLAG M-2 antibody (SIGMA, St Louis, Mis-
souri) was used for immunoprecipitation. PCR consisted of 40
cycles of 941C for 30 s, 601C for 30 s, and 721C for 30 s using Taq
polymerase (Invitrogen). The PCR primers used for ChIP were
as follows: BPAG1F-355MluI; BPAG1Rþ 72XhoI; CLCA2F, TGA-
CACGCGTGCTCCTTTGGTCTTATTTCCCT; and CLCA2R.
DOI: 10.1111/j.0022-202X.2005.23801.x
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